Overview

A Phase 1 Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and with HIV

Status:
NOT_YET_RECRUITING

Trial end date:
2026-12-30

Target enrollment:

Participant gender:

Summary

A Phase 1 Randomized Double Blinded Placebo Controlled, Dose Ranging Trial, of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine (GRAdHIVNE1 Vaccine), Administered to Healthy Adults Living without HIV and Living with HIV, in Southern Africa

Phase:

PHASE1

Details

Lead Sponsor:

International AIDS Vaccine Initiative

Collaborators:

Mutala Trust
Ragon Institute
ReiThera Srl

Treatments:

Disease Vectors